诺和诺德第二季销售增长13%至768.57亿丹麦克朗，经营溢利按年增长29%至334亿丹麦克朗，低于分析师预期的344亿克朗，因美国减肥药市场出现激烈竞争。诺和诺德曾预计，在美国确认减肥药Wegovy及Ozempic的短缺问题解决后，将会终止仿制药的销售许可后，但最终美国当局未有采取行动。诺和诺德重申按固定汇率计算，今年销售增长介乎8%至14%，而经营利润上升介乎10%至16%。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.